Biogen Inc.
 (BIIB)

- NASDAQ
What's your position on ?
Bullish
Bearish
Why are you ish?
Skip
Post
You voted ish on Vote again
Posts appear on the My Feed page of subscribers to this ticker
Last vote:
  • Wed, Jan. 27, 7:19 AM
    • Biogen (NASDAQ:BIIB): Q4 EPS of $4.50 beats by $0.42.
    • Revenue of $2.84B (+7.6% Y/Y) beats by $130M.
    • Shares -2% PM.
    • Press Release
    | Wed, Jan. 27, 7:19 AM | 13 Comments
  • Tue, Jan. 26, 5:30 PM
  • Oct. 21, 2015, 8:09 AM
    • Biogen (NASDAQ:BIIB) Q3 results ($M): Total Revenues: 2,777.9 (+10.6%); Net Product Sales: 2,391.7 (+13.0%).
    • Net Income: 965.6 (+12.7%); EPS: 4.15 (+14.6%); Non-GAAP EPS: 4.48 (+17.9%).
    • Key Product Sales: Tecfidera: 937.4 (+2.3%); Avonex: 685.1 (-7.6%); Tysabri: 497.7 (-0.7%); Plegridy: 99.7 (+999%); Eloctate: 90.6 (+319.4%).
    • 2015 Guidance: Revenue Growth: 8 - 9% from 6 - 8%; EPS: $14.65 - 14.95 from $14.25 - 14.70; Non-GAAP EPS: $16.20 - 16.50 from $15.50 - 15.95.
    • The company announces a corporate restructuring that includes the termination of certain pipeline programs, an 11% reduction in workforce and a $250M reduction in annual operating expenses. The savings will be reinvested to support commercial activities related to Tecfidera and the advancement of high potential pipeline candidates in Alzheimer's disease, multiple sclerosis (MS) and spinal muscular dystrophy. The reduction in headcount will be completed this quarter. Development programs cut include the Phase 3 program for Tecfidera in secondary progressive MS, anti-TWEAK in lupus nephritis and others in immunology and fibrosis.
    • Shares are up 6% premarket on increased volume.
    | Oct. 21, 2015, 8:09 AM | 5 Comments
  • Oct. 21, 2015, 7:32 AM
    • Biogen (NASDAQ:BIIB): Q3 EPS of $4.48 beats by $0.68.
    • Revenue of $2.78B (+10.8% Y/Y) beats by $130M.
    • Shares -0.3% PM.
    | Oct. 21, 2015, 7:32 AM | 8 Comments
  • Oct. 20, 2015, 5:30 PM
    | Oct. 20, 2015, 5:30 PM | 3 Comments
  • Oct. 20, 2015, 9:57 AM
    • Biogen (BIIB +1.2%) reports Q3 results tomorrow before the open. Consensus view is EPS of $3.80 (0%) on revenues of $2.65B (+5.5%).
    | Oct. 20, 2015, 9:57 AM | 9 Comments
  • Jul. 24, 2015, 7:20 AM
    • Biogen (NASDAQ:BIIB) Q2 results ($M): Total Revenues: 2,591.7 (+7.0%); Net Product Sales: 2,198.6 (+6.9%); Joint Business: 337.5 (+11.3%).
    • Net Income: 927.3 (+28.2%); EPS: 3.93 (+30.6%).
    • Key Product Sales: Tecfidera: 883.3 (+12.2%); Avonex: 615.2 (-20.5%); Tysabri: 463.1 (-13.2%); Plegridy: 74.5; Eloctate: 74.3; Alprolix: 54.5.
    • Revenue growth has decelerated the past five quarters: 50.5%; 40.5%; 37.4%; 34.3%; 20.0%; 7.0%.
    • 2015 Guidance: Revenues Growth: 6 - 8% from 14 - 16% due to lower expected Tecfidera growth; EPS: $14.25 - 14.70 from $15.45 - 15.85; Non-GAAP EPS: $15.50 - 15.95 from $16.60 - 17.00.
    • Shares are down 6% premarket on average volume.
    | Jul. 24, 2015, 7:20 AM | 21 Comments
  • Jul. 24, 2015, 6:51 AM
    • Biogen (NASDAQ:BIIB): Q2 EPS of $4.22 beats by $0.12.
    • Revenue of $2.59B (+7.0% Y/Y) misses by $120M.
    | Jul. 24, 2015, 6:51 AM
  • Jul. 23, 2015, 5:30 PM
    | Jul. 23, 2015, 5:30 PM | 10 Comments
  • Jul. 23, 2015, 1:24 PM
    • Biogen (BIIB -0.6%) reports Q2 results tomorrow before the open. Consensus view is EPS of $4.10 (+36%) on revenues of $2.7B (+12%).
    | Jul. 23, 2015, 1:24 PM | 3 Comments
  • Apr. 24, 2015, 7:47 AM
    • Biogen (NASDAQ:BIIB) Q1 results ($M): Total Revenues: 2,554.9 (+20.0%); Net Product Sales: 2,172.3 (+24.6%); Joint Business: 330.6 (+11.4%).
    • Key Product Sales: Tecfidera: 824.9 (+17.8%); Avonex: 692.7 (-9.0%); Tysabri: 462.6 (+4.9%); Plegridy: 61.8; Eloctate: 53.6; Alprolix: 43.1.
    • Net Income: 820.2 (+70.9%); EPS: 3.49 (+72.8%); Operating Earnings: 1,221.6 (+50.8%); Net Earnings Yield: 32.1% (+42.4%).
    • Shares down 2% premarket on modest volume.
    | Apr. 24, 2015, 7:47 AM
  • Apr. 24, 2015, 7:04 AM
    • Biogen (NASDAQ:BIIB): Q1 EPS of $3.82 misses by $0.09.
    • Revenue of $2.55B (+19.7% Y/Y) misses by $110M.
    • Shares +0.63% PM.
    | Apr. 24, 2015, 7:04 AM | 7 Comments
  • Apr. 23, 2015, 5:30 PM
  • Jan. 29, 2015, 4:32 PM
    • Biogen (NASDAQ:BIIB): Q4 EPS of $4.09 beats by $0.31.
    • Revenue of $2.64B (+34.0% Y/Y) in-line.
    • Shares +7.3%.
    | Jan. 29, 2015, 4:32 PM | 6 Comments
  • Jan. 29, 2015, 4:30 PM
    • Biogen Idec (NASDAQ:BIIB) Q4 results ($M): Total Revenues: 2.640.7 (+34.3%); Net Product Sales: 2,287.0 (+42.3%); Joint Business: 304.5 (+13.0%); Royalty: 31.4 (-48.2%); Corporate Partner: 17.8 (-38.0%).
    • Key Product Sales: Avonex: 736.0 (-2.1%); Tysabri: 483.9 (+13.4%); Tecfidera: 916.0 (+81.1%); Fampyra: 18.5 (+6.9%); Fumaderm: 14.4 (+2.1%); Plegridy: 41.1; Alprolix: 40.3; Eloctate: 36.8.
    • COGS: 297.3 (+15.0%); R&D Expense: 500.1 (+18.5%); SG&A Expense: 573.6 (+9.7%); Net Income: 883.5 (+93.2%); EPS: 3.74 (+94.8%); Quick Assets: 1,845.4 (+50.9%).
    • Gross Profit: 2,343.4 (+37.3%); COGS: 11.3% (-14.4%); Gross Margin: 88.7% (+2.2%); Non-GAAP Operating Earnings: 1,269.7 (+66.6%); Operating Earnings Yield: 48.1% (+24.0%); Net Earnings Yield: 33.5% (+43.8%).
    • Net income growth the past four quarters: 12.5%, 47.4%, 75.7%, 93.2%.
    • 2015 Guidance: Revenue growth: 14 - 16%; Non-GAAP EPS: $16.60 - 17.00; EPS: $15.45 - 15.85.
    | Jan. 29, 2015, 4:30 PM
Company Description
Biogen Inc is a biopharmaceutical company. It is engaged in discovering, developing, manufacturing and delivering therapies to patients for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders.
Sector: Healthcare
Industry: Biotechnology
Country: United States